(R)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine | 1376615-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
• 英文别名: (2R)-4-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
• CAS: 1376615-88-1
• 化学式: C₁₆H₁₇F₆N₅
• 分子量: 393.335
• InChiKey: QRFKADFCCAWFBJ-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  60
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  西他列汀 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 以14%的产率得到(R)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
  参考文献：
  名称：

  DRUG DERIVATIVES

  摘要：

  本发明涉及已知活性药物化合物的衍生物。这些衍生物通过是活性化合物的氧化还原衍生物与母体活性化合物相区别。这意味着活性化合物中的一个或多个官能团已转化为另一组，在一项或多项反应中，这可以被认为代表氧化态的变化。我们通常将这些化合物称为氧化还原衍生物。发明中的衍生物可能与原始母体活性药物化合物仅通过单一步骤转换有关，或者可能通过包括一个或多个氧化态变化的几个合成步骤与之相关。在某些情况下，经过两个或更多转换后获得的官能团可能与母体活性化合物处于相同的氧化态（我们将这些化合物包括在我们的氧化还原衍生物定义中）。在其他情况下，发明的衍生物的氧化态可以被认为是与母体化合物不同的。在许多情况下，发明中的化合物本身就具有固有的治疗活性。在某些情况下，相对于母体化合物的相同靶点或靶点，这种活性与母体化合物针对该靶点或靶点的活性一样好或更好。

  公开号：

  US20130225594A1

文献信息

• NOVEL SALTS OF SITAGLIPTIN, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF
  申请人：Indukuri Venkata Sunil Kumar

  公开号：US20140073791A1

  公开（公告）日：2014-03-13

  The present invention relates to pharmaceutically acceptable acid addition salts of sitagliptin, in particular anti-oxidant acid addition salts of sitagliptin and a process for its preparation. The present invention also provides a pharmaceutical composition using the pharmaceutically acceptable acid addition salts of sitagliptin.

  本发明涉及西格列汀的药学上可接受的酸加盐，特别是西格列汀的抗氧化剂酸加盐及其制备方法。本发明还提供了使用药学上可接受的酸加盐的西格列汀的制药组合物。
• [EN] DRUG DERIVATIVES<br/>[FR] DÉRIVÉS DE MÉDICAMENTS
  申请人：REDX PHARMA LTD

  公开号：WO2012063085A3

  公开（公告）日：2012-08-02
• Combined use of DPP-IV inhibitors and gastrin compounds
  申请人：Cruz Antonio

  公开号：US20090054314A1

  公开（公告）日：2009-02-26

  The invention relates to compositions, conjugates, and methods for the prevention and/or treatment of a condition and/or disease comprising a therapeutically effective amount of a DPP-IV inhibitor and a gastrin compound. The combination of a DPP-IV inhibitor and a gastrin compound provides beneficial effects, in particular sustained beneficial effects, in the prevention and/or treatment of conditions and/or diseases for which either a DPP-IV inhibitor or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, obesity, metabolic syndrome and related diseases and disorders. Combinations of a DPP-IV inhibitor and a gastrin compound can be selected to provide unexpectedly additive effects or synergistic effects.
• Combined use of DPP-IV Inhibitors and Gastrin Compounds
  申请人：Cruz Antonio

  公开号：US20100144613A1

  公开（公告）日：2010-06-10

  The invention relates to compositions, conjugates, and methods for the prevention and/or treatment of a condition and/or disease comprising a therapeutically effective amount of a DPP-IV inhibitor and a gastrin compound. The combination of a DPP-IV inhibitor and a gastrin compound provides beneficial effects, in particular sustained beneficial effects, in the prevention and/or treatment of conditions and/or diseases for which either a DPP-IV inhibitor or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, obesity, metabolic syndrome and related diseases and disorders. Combinations of a DPP-IV inhibitor and a gastrin compound can be selected to provide unexpectedly additive effects or synergistic effects.
• US8946224B2
  申请人：——

  公开号：US8946224B2

  公开（公告）日：2015-02-03